Clinical Trial Update: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Disitamab Vedotin alone or with Pembrolizumab for HER2-expressing urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Disitamab Vedotin (RC48-ADC) (disitamab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Urothelial Carcinoma | Phase 2 | Status: RECRUITING